Contact. January Dear Shareholders,

Transcription

1 January Dear Shareholders, As always, I would like to start by wishing you and your loved ones a happy, healthy, and successful new year. Cellectis has been through some challenging times on the stock market as of late. Together with all of you, our employees and senior management have watched the share price slip over the past several months. This steep decrease in share price adversely affects all Cellectis shareholders: institutional investors, individual shareholders and the company s employee shareholders, as well as its management team and founders. I would like to express my gratitude to all of you, who have placed your trust in us and lent us your support for a number of years now. I understand your current position. Contact Cellectis Shareholder relations 8 rue de la Croix Jarry Paris France Phone: +33 (0) investors@cellectis.com actionnaires@cellectis.com Website: Cellectis Securities Services: Société Générale Securities Services (affiliate 042) Photo credits: D. Morganti; Cellectis; DR Since its founding nearly 14 years ago, Cellectis has always shown that it can reinvent itself so as to remain at the forefront of innovation in the biotechnology industry by adapting to market requirements without ever resting on our laurels. Our know-how and expertise are recognized around the world by many important players in the business, institutional and academic worlds. At the same time, growing pains are still an important issue faced by our industry, where competition is intense and innovation can be disruptive. The industry s promises are difficult to quantify precisely. Similarly, predicting the time required to transform the most promising innovations into market-ready products is a complex and elusive task. Without a doubt, this is one of the reasons for nervousness on the part of investors especially investment funds the main cause behind the wide swings in the market valuations of listed companies like Cellectis.

2 continued In Europe and North America, as in the rest of the world, biotechnology companies use equity to finance their business activities and their expansion. Only in the last few years have actual sales begun to account for a more significant percentage of their revenue. This dependence on capital financing contributes to the instability of biotech valuations. Aside from purely financial considerations, a spectacular paradigm shift has been upending business models across the entire biotech industry for the last few years. Cellectis has not been immune to this phenomenon. Since the beginning of, sales of genome engineering tools for research, which represented a sizeable proportion of the Group s revenue, have faced strong competitive pressure throughout the world and particularly in the North American market. This trend reversal has led to a substantial operating loss for that division, which has had an impact on the Group s overall earnings. Over this same period, our therapeutics and agribusiness activities have made significant strides forward in their development plans. This situation has now led us to adjust our structure in order to meet our strategic targets for value creation in the short and mid-term. Alongside an operating cost reduction program, we wish to focus our human and financial resources on our two strategically key fields, while maintaining a service business essentially dedicated to the bio-pharmaceutical industry. In line with this refocusing effort, we have simplified our legal structure by merging Ectycell s ips cell facility into Cellectis bioresearch. Caisse des Dépôts is working with us in this tie-up, having subscribed for Cellectis bioresearch s 3.5 million capital increase, in accordance with the commitments made under the partnership initiated in January This rationalization is necessary in order for us to meet the expectations of the market and our shareholders, and to attain our strategic value creation targets. To all of you who have placed your trust in Cellectis, I would like once again to express my gratitude and to assure you that we will do whatever it takes to measure up to our ambitions. André Choulika Chairman and Chief Executive Officer

3 Strategy A necessary strategic repositioning From genome engineering tools to genome engineering-derived products A sudden and spectacular paradigm shift has been upending business models across the entire biotech industry over the past two years. Nucleases especially meganucleases and TALENTM, which still constitute recent breakthroughs as far as both science and business are concerned have created a sensation. Huge numbers of disruptive technologies have emerged over the last three years. Cellectis was one of the main contributors to this. However, these nucleases have now become a commodity that most market participants, including academic institutions, know how to manufacture. The cost of producing them has plummeted. Against this backdrop, back in 2008, we resolved to stay ahead of the curve. But accelerating competition led to deep-seated pressure on a global scale, particularly in the first half of. Starting in 2008, we began making investments to enhance our differentiated expertise in the market s most promising segments: therapeutics (particularly the fight against cancer) and agribusiness (including industrial and food oils). We are now looking to adapt our structure even more rapidly so that we can deliver on our targets in this increasingly intense competitive environment. Hence our decision to focus on therapeutics and agribusiness while at the same time resizing and reorganizing. Cellectis CANCER THERAPY T-cell platform Adoptive immunotherapy (ALL, CLL) Solid tumors CART Innovation REGENERATIVE MEDICINE Diabetes Cellectis plant sciences Seed varieties: enhancing industrial and food oils Bio-fuels: microalgae engineering Cellectis bioresearch Services: Customized nucleases Cell engineering ips Engineering Hub ProduCts: Nucleases (meganucleases and TALENTM), cells for drug discovery and imaging, kits, biomanufacturing

4 Spotlight on therapeutics cancer treatment is seen to offer a number of advantages in terms of clinical outcomes, cost and market access. We are simultaneously developing a solid tumor treatment program to be rolled out at the end of, building 12 CARs (chimeric antigen receptors) capable of recognizing certain antigens present in solid tumors (EU, Since 2008, Cellectis has built an innovative approach STA, EGFRvIII, ROI, etc.). We plan on getting one of our to the development of therapeutic applications based products into the clinical development stage in early, on its know-how in genome engineering. In this area, with a pipeline of five to six CAR T-cells acting on different Cellectis draws on its expertise in key technologies such types of solid tumors. as adoptive immunotherapy for cancer treatment (rewe have also joined forces with the Danish group Novo engineered T-cells) and pluripotent stem cells. Nordisk to develop a treatments for diabetes. At our stem The Company is currently working on adoptive cell based regenerative medicine facility in Gothenburg, immunotherapy in partnership with University College we are developing new approaches to treating the type 1 London (UCL) to develop a promising new treatment for version of this disease. certain types of cancer (chronic lymphocytic leukemia, Therapeutics is our new focus. We are developing acute lymphoblastic leukemia and B-cell non-hodgkin disruptive innovations in the fight against cancer that will lymphoma). enable us to design new treatments in partnership with The T-cells we engineer with our state of the art technology major pharmaceutical companies. Our current work will are unlike anything else currently under development: they secure us a privileged position in the future development Lead identification Lead optimization Preclinical Phase I are allogeneic designed for compatibility with each of CAR T-cells, expected to become one of the most Oncology recipient s immune system. This new breakthrough in promising areas of cancer medicine. Cellectis Blood cancer / Lymphoid leukemia (UCART19) / Target: CD /2017 Preclinical Phase I Blood cancer / Lymphoid leukemia (UCART19) / Target: CD19 Solid tumors / Lung, pancreas, colorectal cancer / Target: 5T4 2016/ Solid tumors / Lung, pancreas, colorectal cancer / Target: 5T4 Lead identification Lead optimization Oncology Regenerative medicine Diabetes: Target: beta cells Cellectis-Novo Nordisk alliance Other applications: Hemophilia / Target: hepatocytes Regenerative medicine Diabetes: Target: beta cells Cellectis-Novo Nordisk alliance

5 Spotlight on plants Cellectis plant sciences Founded in 2010, Cellectis plant sciences is among the world s leading specialists in plant genome engineering. Based in New Brighton, Minnesota (United States) and in Paris, Cellectis plant sciences has developed key technologies for the development of new plant varieties by implementing engineered agronomic traits in oil crops. Thanks to its recognized expertise spanning a wide range of plants (soybeans, tobacco, potatoes, rapeseed, wheat, rice and microalgae) and its know-how in plant biotechnology, Cellectis has been able to develop innovative products with prominent partners (Medicago/ Mitsubishi, Bayer, SESVanderHave) and forge alliances for access to high-potential markets. Cellectis plant sciences focuses on three main areas: enhancing food oils (soybean, rapeseed); producing biofuels by reprogramming microalgae; a platform for collaboration between research partners and agri-food companies. The high-potential activities and products developed by Cellectis plant sciences have opened up considerable growth prospects, in particular a significant increase in value over the next three years after the first traits are planted (developed in-house or with partners). Initiation Phenotype Scale up Licensed Phenotype Scale up Licensed In house programs Soybean oil New plant oils Food for human consumption In house programs Algae oil Green chemistry Soybean oil Initiation New plant oils Food for human consumption Algae oil Green chemistry License & Partnerships CPS Platform 3-5 key partners Bioproduction Tool Tobacco XT/FT lines License & Partnerships CPS technologies: Gene stacking / Transformation technology / Non-GM CPS Platform All crops, licensing Bioproduction Tool Tobacco XT/FT lines CPS technologies: Gene 3-5 key partners

6 Spotlight on Tools and Services Cellectis bioresearch Founded in 2008, Cellectis bioresearch has positioned itself as an expert provider of tools and services combining targeted DNA editing and stem cell technology. Located in Paris and Gothenburg (Sweden), Cellectis bioresearch works in key fields such as induced pluripotent stem cells (ips cells) and genome engineering, and has developed expertise in nucleases and genetic targeting. Since its inception, Cellectis bioresearch has marketed various solutions for the life sciences sector: tools for specific applications, notably drug discovery and testing; engineered products; services adapted to all cell engineering projects. ScéilTM Launched in July, Scéil is the first opportunity for individuals to store their own induced pluripotent stem cells (ips cells) so as to benefit, if necessary, from future regenerative medicine treatments. The program s availability in various geographic regions is subject to prevailing laws and regulations. Trading data W Exchange listing Alternext NYSE Euronext, Paris Ticker code FR ALCLS IPO date February 6, 2007 Trading indices Alternext Allshare, Next Biotech, Oseo Innovation Reuters ALCLS.PA Bloomberg ALCLS:FP Legal form French Société Anonyme with a board of directors Chief Executive Officer André Choulika Chief Financial Officer Pierre Schwich Disclaimer This publication and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe for shares in Cellectis in any country. This publication contains forward-looking statements that relate to the Company s objectives based on the current expectations and assumptions of the Company s management only and involve unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements.